In a regulatory filing, Fulcrum Therapeutics disclosed that its CEO Alex Sapir bought 43.4K shares of common stockon March 4th in a total transaction size of $492K.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on FULC:
- Fulcrum Therapeutics to Participate at the Leerink Partners Global Biopharma Conference
- Fulcrum Therapeutics price target raised to $15 from $13 at Piper Sandler
- Fulcrum Therapeutics price target raised to $17 from $14 at H.C. Wainwright
- Fulcrum Therapeutics files $350M mixed securities shelf
- Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2023
